Cigna Stock Slips as Rising Medical Costs Overshadow Q2 Earnings Beat

Cigna (NYSE: CI) shares slipped over 1% in pre-market trading Tuesday despite the health insurer reporting second-quarter results that surpassed analyst expectations and raising its full-year earnings forecast. The negative investor reaction appeared to stem from rising medical costs and a guidance update that offered only a marginal beat over Wall Street projections.

Second-Quarter Performance

The company reported strong top- and bottom-line results for the period. Key figures from the earnings release include:

• Adjusted Earnings Per Share: $7.78, beating the analyst consensus of approximately $7.60.
• Total Revenue: $71.7 billion, a 7% increase year-over-year and ahead of estimates of around $70.18 billion.

Outlook Tempered by Cost Pressures

Ad

Despite the solid quarter, underlying metrics and a conservative outlook weighed on the stock. Cigna nudged its full-year 2026 adjusted EPS guidance higher to at least $30.45, an increase of $0.10. However, this revised forecast is only slightly above the consensus estimate of $30.41, suggesting limited upside.

More significantly, Cigna's medical care ratio (MCR) — a key metric showing the portion of premiums spent on medical claims — rose to 84.5% from 83.2% a year ago. This increase points to the sector-wide pressure from elevated healthcare utilization that has concerned investors. The company also reported a year-over-year decline in its medical customer base.

Broader Context

The market's muted response reflects a "sell the news" dynamic, where a well-anticipated earnings beat was not enough to overcome concerns about profitability pressures. The report is the first under new CEO Brian Evanko, adding a layer of leadership transition scrutiny for investors. The broader managed care sector remains under a microscope due to high medical cost trends and regulatory uncertainty, contributing to a cautious stance on the stock despite its resilient revenue growth.